Success Story: Strategic RFE Response Leads to NIW Approval for a Computational Biophysics Software Engineer
On March 23rd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Research Assistant in the Field of Computational Biophysics (Approval Notice).
General Field: Computational Biophysics
Position at the Time of Case Filing: Graduate Research Assistant
Country of Origin: Turkey
State of Residence at the Time of Filing: California
Approval Notice Date: March 23rd, 2026
Processing Time: 19 months, 15 days (Premium Processing Upgrade Requested)
Case Summary:
North America Immigration Law Group is pleased to share the successful approval of an I-140 EB-2 National Interest Waiver (NIW) petition for the client, a computational biophysics researcher who received a Request for Evidence (RFE) during adjudication. Despite the RFE, the petition was approved after a focused response that clarified both the national importance of the proposed endeavor and the client’s strong positioning to advance it.
The Proposed Endeavor
The client holds a Ph.D. in biophysics and quantitative biology and works in the United States in a scientific software engineering role supporting life sciences research. As an expert in computational biophysics, the client’s proposed endeavor is to continue developing state-of-the-art computational biophysics tools as commercial software to understand viral mechanisms, identify drug-binding pockets in proteins, and simulate protein–cell membrane systems. We framed this endeavor as an area of clear, substantial merit and national importance because better computational tools can shorten discovery cycles and improve decision-making in pharmaceutical and biotechnology development, especially when they help researchers evaluate mechanisms and candidate compounds more efficiently.
Establishing a Strong Record of Success
To demonstrate that the client was well-positioned, we presented a record of peer-reviewed output, independent reliance, and professional trust, while explaining how an adjudicator should interpret these metrics rather than treating them as self-evident:
- Publications: 3 peer-reviewed journal articles (including first-authored and co-first-authored work) and 4 conference abstracts (all first-authored)
- Citations: 108 citations to the published body of work
- Peer review service: at least 2 completed reviews
- Competitive support: research support connected to major U.S. biomedical and energy research agencies and nationally significant supercomputing and biotechnology initiatives
We also placed the citation record in context. In addition to total citations, the filing highlighted field-and year-normalized impact indicators showing that two publications performed at top citation-percentile levels for their publication years. We used this not as a numbers-only argument, but as a way to show that independent researchers relied on the client’s findings at an unusually strong rate relative to typical citation patterns in the broader field.
Navigating the RFE
The RFE questioned whether the client’s prior work established a strong positioning to advance the proposed endeavor. Our response focused on three clear anchors that adjudicators can evaluate: a coherent technical thread across the client’s computational methods for viral and biomolecular systems; independent reliance shown through citations from researchers building on the client’s findings in adjacent areas; and external trust signals reflected in peer-review invitations and competitively supported research environments aligned with nationally relevant science and technology priorities.
The Result
USCIS approved the NIW petition after the RFE response. This outcome reflects a persuasive presentation that the endeavor has substantial merit and national importance, and that the client is well-positioned to advance it through peer-reviewed research, documented independent reliance, and credible professional trust indicators. We look forward to the client’s continued contributions to computational biophysics software that supports faster, more efficient discovery in pharmaceuticals and biotechnologies in the United States.